PARP1 and neoplasm: UNI66, another inhibitor of BRD4, suppresses HR by inhibiting BRD4-mediated transcription of CtBP-interacting protein (CtIP) and RAD51, thereby inducing synthetic lethality in PARP1-deficient cells and enhancing tumor sensitivity to PARPis [64].